The EMBO Journal

bit.bio Secures Foundational United States Patent for opti-oxTM, its Cell Programming Technology That Uses Genomic Safe Harbour Sites

Retrieved on: 
水曜日, 7月 26, 2023
Science, Stem Cells, Other Science, Biotechnology, Health, Medical Devices, Health Technology, Genetics, CRISPR, Eukaryote, International Society for Stem Cell Research, Advanced Materials, Science Advances, ISSCR, KAT2B, Research, Brain, Cell, RBM3, Genetic code, Gene silencing, Transgene, Patent, Patient, Data, Clonal, The EMBO Journal, Biology, Synthetic biology, International Society, Vaccine

bit.bio, the company coding human cells for novel cures, has secured a foundational U.S. patent for opti-ox , its precision cell programming and manufacturing technology.

Key Points: 
  • bit.bio, the company coding human cells for novel cures, has secured a foundational U.S. patent for opti-ox , its precision cell programming and manufacturing technology.
  • opti-ox uses a dual genomic safe harbour approach to cell programming, and the granted U.S. patent covers the use of opti-ox to deterministically activate genetic code in any eukaryotic (cell with a nucleus) cell type.
  • The ability to produce defined human cell types with consistency and scale sets new standards in biological research.
  • Genomic safe harbour sites protect the integrity of the cell and enable faithful activation of transgenes by avoiding gene silencing.

Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board

Retrieved on: 
火曜日, 12月 6, 2022
Creativity, Article (publishing), LMU, Associate, Asthma, Head, BVXV, Coronavirus, Immunology, Weizmann Institute of Science, Annual report, Degenerative disease, VHH, Communication, Neutralizing antibody, University Medical Center, Security (finance), SAB, The EMBO Journal, Centre for Journalism (University of Southern Denmark), Motivation, Cancer, Princeton University, Psoriasis, Drug development, Macular degeneration, Infection, Virology, Research, Professor, Severe acute respiratory syndrome coronavirus 2, BiondVax, Risk, Professional, University, COVID-19, UMG, Therapy, Max Planck Society, Pharmaceutical industry

Matthias Dobbelstein has been appointed a member of the company’s Scientific Advisory Board (SAB).

Key Points: 
  • Matthias Dobbelstein has been appointed a member of the company’s Scientific Advisory Board (SAB).
  • Professor Dobbelstein has served as Director of the Institute of Molecular Oncology at the University Medical Center Göttingen (UMG), Germany since 2005 and is also an Associate Member of the Max Planck Institute for Multidisciplinary Sciences (MPI-NAT).
  • In addition, Professor Dobbelstein, together with Professor Görlich, is collaborating with BiondVax under a five-year strategic research agreement for the discovery, characterization and cloning of additional NanoAbs for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, asthma and macular degeneration.
  • Professor Ruth Arnon, head of BiondVax’s SAB and The Paul Ehrlich Professor of Immunology at the Weizmann Institute of Science, Israel, commented, “We are pleased to welcome Matthias’ broad and relevant expertise to BiondVax’s SAB.

BiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies

Retrieved on: 
木曜日, 3月 24, 2022
Company, Drug development, Risk, UMG, European Investment Bank, Plasma protein binding, The EMBO Journal, Investment banking, Marketing, Coronavirus, Macular degeneration, Psoriatic arthritis, BVXV, Probability, CEO, Severe acute respiratory syndrome coronavirus 2, Psoriasis, U.S. Securities and Exchange Commission, Laboratory, Security (finance), Technology, Max Planck Society, BiondVax, Flávio Kenup, MPI, Nasdaq, COVID-19, EIB, Asthma, VHH, GMP, University Medical Center, Patient, Molecular oncology, Infection, Pharmaceutical industry, Vaccine, Fine chemical, Sanofi

BiondVax will have an exclusive option for an exclusive worldwide license at pre-agreed commercial terms for further development and commercialization of each generated NanoAb.

Key Points: 
  • BiondVax will have an exclusive option for an exclusive worldwide license at pre-agreed commercial terms for further development and commercialization of each generated NanoAb.
  • BiondVax is planning a rapid development path that leverages the company's expertise and capabilities in biological drug development and manufacturing.
  • BiondVax anticipates conducting a preclinical proof of concept study of inhaled COVID-19 NanoAbs in 2022 with initial human clinical trials results in 2023.
  • With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms, beginning with an innovative nanosized antibody (NanoAb) pipeline.

BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany

Retrieved on: 
水曜日, 12月 22, 2021
Annual report, Technology, Max, BVXV, COVID-19, Clinical trial, U.S. Securities and Exchange Commission, Drug development, Risk, Patient, Max Planck Society, Infection, Organic compound, EIB, Company, Antibody, Severe acute respiratory syndrome coronavirus 2, Multimedia, Biophysical chemistry, The EMBO Journal, Marketing, Compugen (Israeli company), Therapy, Asthma, Macular degeneration, UMG, Security (finance), GMP, Flávio Kenup, Molecular oncology, Nasdaq, European Investment Bank, Omicron, Psoriatic arthritis, Max Planck Institute for Biophysical Chemistry, University Medical Center, Coronavirus, Inhalation, CEO, Psoriasis, MPG, BiondVax, Pharmaceutical industry, Vaccine, Sanofi, Alpha, Delta

Given the potential of additional emerging VoCs, the BiondVax-MPG-UMG collaboration covers development of new NanoAbs as needed during the evolution of COVID-19.

Key Points: 
  • Given the potential of additional emerging VoCs, the BiondVax-MPG-UMG collaboration covers development of new NanoAbs as needed during the evolution of COVID-19.
  • BiondVax is planning a rapid development path that leverages the company's expertise and capabilities in biological drug development and manufacturing.
  • The technology is a great fit to our manufacturing site in Jerusalem and our experience and expertise in biological drug development.
  • Professor Dirk Grlich, Director at the Max Planck Institute for Biophysical Chemistry, commented, "We believe that the innovative platform developed at the Max Planck Institute for Biophysical Chemistry and the University Medical Center of Gttingen has great potential to provide patients with superior therapies.